These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 31242517)

  • 21. Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice.
    Castellano D; Puente J; de Velasco G; Chirivella I; López-Criado P; Mohedano N; Fernández O; García-Carbonero I; González MB; Grande E
    BMC Cancer; 2014 Oct; 14():779. PubMed ID: 25342282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The current status of checkpoint inhibitors in metastatic bladder cancer.
    Fahmy O; Khairul-Asri MG; Stenzl A; Gakis G
    Clin Exp Metastasis; 2016 Oct; 33(7):629-35. PubMed ID: 27380916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
    Ellis PM; Vella ET; Ung YC
    Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma.
    Hussain SA; Birtle A; Crabb S; Huddart R; Small D; Summerhayes M; Jones R; Protheroe A
    Eur Urol Oncol; 2018 Dec; 1(6):486-500. PubMed ID: 31158093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent Clinical Trials Explore Immunotherapies for Urothelial Carcinoma.
    Balar AV
    Oncology (Williston Park); 2019 Apr; 33(4):132-6. PubMed ID: 30990565
    [No Abstract]   [Full Text] [Related]  

  • 26. Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy.
    Sonpavde G; Pond GR; Mullane S; Ramirez AA; Vogelzang NJ; Necchi A; Powles T; Bellmunt J
    BJU Int; 2017 Apr; 119(4):579-584. PubMed ID: 27700015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma.
    Koshkin VS; Grivas P
    Curr Oncol Rep; 2018 Apr; 20(6):48. PubMed ID: 29644490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune checkpoint inhibitors: a new frontier in bladder cancer.
    Kates M; Sopko NA; Matsui H; Drake CG; Hahn NM; Bivalacqua TJ
    World J Urol; 2016 Jan; 34(1):49-55. PubMed ID: 26487055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?
    Roviello G; Catalano M; Nobili S; Santi R; Mini E; Nesi G
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy Advances in Urothelial Carcinoma.
    Jain RK; Snyders T; Nandagopal L; Garje R; Zakharia Y; Gupta S
    Curr Treat Options Oncol; 2018 Dec; 19(12):79. PubMed ID: 30554335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies.
    Sotelo M; Alonso-Gordoa T; Gajate P; Gallardo E; Morales-Barrera R; Pérez-Gracia JL; Puente J; Sánchez P; Castellano D; Durán I
    Clin Transl Oncol; 2021 Apr; 23(4):882-891. PubMed ID: 32897497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
    Farina MS; Lundgren KT; Bellmunt J
    Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer.
    Stühler V; Maas JM; Bochem J; da Costa IA; Todenhöfer T; Stenzl A; Bedke J
    World J Urol; 2019 Sep; 37(9):1773-1784. PubMed ID: 30374610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging role of checkpoint inhibition in localized bladder cancer.
    Singh P; Black P
    Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A network meta-analysis of the PD(L)-1 inhibitors in the salvage treatment of urothelial bladder cancer.
    Rassy EE; Bakouny Z; Aoun F; Haddad FG; Sleilaty G; Assi T; Kattan J
    Immunotherapy; 2018 Jun; 10(8):657-663. PubMed ID: 29562804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Systemic chemotherapy for transitional cell carcinoma of the urothelium].
    Lehmann J; Retz M; Hack M; Siemer S; Stöckle M
    Onkologie; 2003 Oct; 26 Suppl 4():18-25. PubMed ID: 14605452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy in Lung Cancer.
    Du L; Herbst RS; Morgensztern D
    Hematol Oncol Clin North Am; 2017 Feb; 31(1):131-141. PubMed ID: 27912829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy for metastatic urothelial carcinoma: status quo and the future.
    Necchi A; Rink M; Giannatempo P; Raggi D; Xylinas E
    Curr Opin Urol; 2018 Jan; 28(1):1-7. PubMed ID: 29028766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Atezolizumab (Tecentriq
    Bernard-Tessier A; Bonnet C; Lavaud P; Gizzi M; Loriot Y; Massard C
    Bull Cancer; 2018 Feb; 105(2):140-145. PubMed ID: 29290331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.